Clinicopathological and molecular features of myeloid sarcoma as initial presentation of therapy-related myeloid neoplasms: a single institution experience

Int J Hematol. 2014 Nov;100(5):457-63. doi: 10.1007/s12185-014-1659-y. Epub 2014 Sep 11.

Abstract

Therapy-related myeloid neoplasms (t-MN) have a common origin in prior cytotoxic therapy and/or radiation. These neoplasms include therapy-related acute myeloid leukemia, myelodysplastic syndrome (t-MDS), and myelodysplastic/myeloproliferative neoplasms (t-MDS/MPN). Myeloid sarcoma (MS), on the other hand, is a rare disease manifesting as an extramedullary collection of immature cells of myeloid lineage. Rarer still is therapy-related MS (t-MS), which has not been adequately studied due to its rarity and its lack of recognition as a unique entity among other t-MN. Here, we report what is to our knowledge the first case series of t-MS, with the aim of investigating and establishing salient clinicopathological and molecular features of this entity.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Bone Marrow / pathology
  • Cytogenetic Analysis
  • Databases, Factual
  • Female
  • Humans
  • Immunophenotyping
  • Leukemia, Myeloid, Acute / genetics
  • Leukemia, Myeloid, Acute / pathology
  • Male
  • Middle Aged
  • Mutation
  • Neoplasms, Second Primary / diagnosis
  • Neoplasms, Second Primary / genetics*
  • Neoplasms, Second Primary / mortality
  • Neoplasms, Second Primary / pathology*
  • Neoplasms, Second Primary / therapy
  • Phenotype
  • Proto-Oncogene Proteins B-raf / genetics
  • Retrospective Studies
  • Sarcoma, Myeloid / diagnosis
  • Sarcoma, Myeloid / genetics*
  • Sarcoma, Myeloid / mortality
  • Sarcoma, Myeloid / pathology*
  • Sarcoma, Myeloid / therapy
  • fms-Like Tyrosine Kinase 3 / genetics

Substances

  • fms-Like Tyrosine Kinase 3
  • Proto-Oncogene Proteins B-raf